The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CC-486 and Venetoclax for Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05287568
Recruitment Status : Recruiting
First Posted : March 18, 2022
Last Update Posted : May 16, 2024
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.

Condition or disease Intervention/treatment Phase
AML Drug: Venetoclax Drug: CC-486 Phase 1

Detailed Description:

Subjects confirmed eligible will be admitted to the hospital for cycle 1, day 1. Venetoclax will be administered days 1-3, with the following schema:

100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter.

Subjects taking concomitant CYP3A4 inhibitors will be given the appropriate reduced doses of venetoclax.

Subjects will be monitored inpatient for tumor lysis syndrome (TLS) for at least 24 hours after administration of the venetoclax target dose. Venetoclax will continue at 400 mg daily until day 28, the completion of cycle 1.

During dose escalation, subjects will be accrued into two cohorts using two different doses of CC-486 (cohort 1=200 mg, cohort 2=300 mg, both to be administered orally on days 1-14 of a 28-day cycle).

Two bone marrow biopsies will be performed during the first cycle: day 4 or 5 (+2 days), and day 28. The day 28 bone marrow will be used for efficacy purposes. Subsequent cycles will have response assessment bone marrow biopsies day 28 of every cycle for subjects who have not responded (CR/CRi/MLFS); after a response occurs (CR/CRi/MLFS), subjects will have bone marrow biopsies on day 28 of every 3rd cycle until they have been on the study for one year, at which point they will have a bone marrow biopsy every 6 months until study discontinuation.

Once the MTD is established, or in the absence of an MTD, a recommendation for a CC-486 dose with venetoclax is made, the study will progress to the expansion phase. For the expansion phase, 10 subjects will be recruited. These will be patients with relapsed/refractory (R/R) disease who have never received venetoclax. On day 1 of cycle 1, subjects will receive CC-486 at the MTD or recommended CC-486 dose as determined from Phase I, and this will continue daily through day 14. Venetoclax will be dose escalated, as above, from 100 to 200 to 400 mg on days 1, 2 and 3, respectively, with inpatient monitoring for TLS, and with appropriate dose reduction if administered with a CYP3A4 inhibitor. Bone marrow biopsies will occur on day 4 or 5 (+2) and on day 28 of cycle 1. Subsequent response assessment bone marrow biopsies will occur on day 28 of every 3rd cycle for subjects who have achieved a response for 1 year from study entry and then every 6 months until study discontinuation, or on day 28 of every treatment cycle for subjects who do not achieve a response.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: This is an open label, dose escalation phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CC-486 and Venetoclax for Acute Myeloid Leukemia
Actual Study Start Date : December 19, 2022
Estimated Primary Completion Date : March 23, 2027
Estimated Study Completion Date : March 2029


Arm Intervention/treatment
Experimental: Cohort 1 CC-486 200 mg
CC-486 200 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
Drug: Venetoclax
Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with > 1,000-fold higher affinity to BCL-2 (Ki < 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki > 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
Other Name: ABT-199, Abbvie

Drug: CC-486
An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.

Experimental: Cohort 2 CC-486 300 mg
CC-486 300 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
Drug: Venetoclax
Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with > 1,000-fold higher affinity to BCL-2 (Ki < 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki > 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
Other Name: ABT-199, Abbvie

Drug: CC-486
An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.

Experimental: Dose Expansion Cohort
CC-486 MTD will be determine following the completion of Cohort 1 and Cohort 2 with venetoclax at 400 mg/day PI regimen for 28 days.
Drug: Venetoclax
Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with > 1,000-fold higher affinity to BCL-2 (Ki < 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki > 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
Other Name: ABT-199, Abbvie

Drug: CC-486
An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.




Primary Outcome Measures :
  1. Determine the maximum tolerated dose of CC-486 in combination with venetoclax [ Time Frame: 7 years ]
    Standard phase I 3+3 design. The first 3 subjects will be assigned to cohort 1. If none of the first three subjects' experiences DLT, escalation to cohort 2 is permitted. If one of the first three subjects' experiences DLT, a total of six subjects will be required in that dose cohort, and escalation will only be permitted if five of six subjects do not experience DLT. If more than one DLT is observed in the second cohort, this will be determined to be the maximally administered dose, and three more subjects will be enrolled in the first cohort if only three were previously treated at that dose. The MTD will be the cohort in which ≤1/6 subjects have dose limiting toxicity at the dose prior to the maximally administered dose. If the second cohort has ≤1/6 subjects with a DLT, the MTD will not have been reached, and the recommended dose for the expansion cohorts will be determined based on the safety, efficacy and pharmacodynamic outcomes from subjects treated in the first two cohorts.


Secondary Outcome Measures :
  1. Adverse event profile of CC-486 in combination with venetoclax [ Time Frame: 7 years ]
    Subject safety will be assessed by reviewing AEs during planned and unplanned visits and physical and laboratory examinations from the time subject receives the first dose of study drug until safety follow up. AEs related to a procedure after consent will also be assessed. The investigator will assess and record AEs in detail including the date of onset, event diagnosis (if known) or sign/symptom, severity, time course (end date, ongoing, intermittent), relationship of the AE to the study drug, and any action taken. For SAEs considered unrelated to study drug, the investigator will provide another cause for the event. AEs may be recorded as the result of a response to a query, an observation by site personnel, or due to a report from a subject. All AEs will be followed to a satisfactory conclusion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject must have confirmation of non-APL AML by WHO criteria46 and have undergone at least one line of therapy (dose escalation and dose expansion cohorts).
  2. Transplant eligible patients can participate in the study and they are allowed to proceed with stem cell transplantation at any time during the study.
  3. Subject must have a projected life expectancy of at least 12 weeks.
  4. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 2.
  5. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.
  6. Subject must have adequate liver function as demonstrated by:

    1. aspartate aminotransferase (AST) ≤ 3.0 × ULN*
    2. alanine aminotransferase (ALT) ≤ 3.0 × ULN*
    3. bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome* * Unless considered due to leukemic organ involvement
  7. Non-sterile male subjects must use contraceptive methods with partner(s) at least prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug. No contraception is required if male subjects are surgically sterile (vasectomy with medical assessment confirming surgical success) or if the male subject has a female partner who is postmenopausal or permanently sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  8. Female subjects must be either:

    1. Postmenopausal; defined as Age > 60 years with no menses for 12 or more months without an alternative medical cause; OR
    2. Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); OR
    3. If subject is of childbearing potential, use of contraception is required while on study treatment and for 6 months after the last dose.
  9. Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed screening or procedures.
  10. Subject is informed that consumption of the following fruits is prohibited 3 days prior to the initiation of study treatment and throughout participation: grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit.

Exclusion criteria:

  1. Subject has known active CNS involvement from AML.
  2. Subject is known to be positive for HIV. HIV testing is not required.
  3. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate.
  4. Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:

    1. Significant active cardiac disease within the previous 6 months including: New York Heart Association heart failure > class 2, unstable angina, or myocardial infarction.
    2. Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia.
  5. Subject has a malabsorption syndrome or other condition that precludes enteral route of administration. This includes history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease (e.g. sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
  6. Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal). Uncontrolled is defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment.
  7. Subject has a history of other malignancies prior to study entry, with the exception of:

    1. Adequately treated in situ carcinoma of the breast or cervix uteri
    2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
    3. Prostate cancer not requiring therapy beyond hormonal therapy
    4. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
  8. Subject has a white blood cell count > 25 × 109/L. Note: hydroxyurea or apheresis are permitted to meet this criterion.
  9. Any subject who is a candidate for intensive induction therapy and agrees to receive this therapy.
  10. Pregnant or breast-feeding females. A pregnancy test will be obtained at the time of screening.
  11. Known or suspected hypersensitivity to azacitidine or mannitol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05287568


Contacts
Layout table for location contacts
Contact: Derek Schatz 7208480628 derek.schatz@cuanschutz.edu

Locations
Layout table for location information
United States, Colorado
CU Anschutz Medical Campus Recruiting
Aurora, Colorado, United States, 80045
Contact: Derek Schatz       derek.schatz@cuanschutz.edu   
Contact: Constance Brecl    3035078221    constance.brecl@cuanschutz.edu   
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Derek Schatz       derek.schatz@cuanschutz.edu   
Contact: Constance Brecl       constance.brecl@cuanschutz.edu   
Principal Investigator: Daniel Pollyea, MD         
Sub-Investigator: Peter Forsberg, MD         
Sub-Investigator: Jonathan Gutman, MD         
Sub-Investigator: Brad Haverkos, MD         
Sub-Investigator: Manali Kamdar, MD         
Sub-Investigator: Tomer Mark, MD         
Sub-Investigator: Daniel Sherbenou, MD         
Sub-Investigator: Clay Smith, MD         
Sub-Investigator: Jagar Jasem, MD         
Sub-Investigator: Maria Amaya, MD PhD         
Sub-Investigator: Christine McMahon, MD         
Sub-Investigator: Marc Schwartz, MD         
Sub-Investigator: Steven Bair, MD         
Sponsors and Collaborators
University of Colorado, Denver
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Daniel E Pollyea, MD University of Colorado, Denver
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT05287568    
Other Study ID Numbers: 20-1319.cc
First Posted: March 18, 2022    Key Record Dates
Last Update Posted: May 16, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: At this time, there is no plan to share individual patient data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid, Acute
Leukemia
Neoplasms by Histologic Type
Neoplasms
Hematologic Diseases
Leukemia, Myeloid
Venetoclax
Cc-486
Antineoplastic Agents